NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Vanda Pharmaceuticals Inc. (VNDA) Stock Analysis

Vanda Pharmaceuticals Inc. (VNDA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VNDA

$4.01

−$0.16 (−3.84%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VNDA with… →

VNDA Key Statistics

As of Oct 21, 2026
Trading
Open
$4.18
Previous Close
$4.17
Day's Range
3.97–4.18
52-Week Range
3.97–9.94
Volume
1.09M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.69
Valuation
Market Cap
$242.46M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
20.05
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.23
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.12
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.63
Financials (FY)
Revenue (FY)
$216.11M+8.72%
Net Income (FY)
−$220.47M
Profit marginThe share of revenue left as profit after all costs and taxes.
−127.41%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
60.46M
1-Year Return
−24.20%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
964.86K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VNDA closed at $4.01, −24.20% over 1 year.

Vanda Pharmaceuticals Inc. (VNDA) has a market capitalization of $242.46M.

In fiscal 2025, VNDA reported revenue of $216.11M.

VNDA Stock Return by Calendar Year

Vanda Pharmaceuticals Inc. (VNDA) 10-year return: what $10,000 became

1 year
$10,000 $7,580
−24.20%
5 years
$10,000 $2,223
−77.77%
10 years
$10,000 $2,533
−74.67%

If you had invested $10,000 in Vanda Pharmaceuticals Inc. (VNDA) 10 years ago, at the close on October 21, 2016, it would have been worth $2,533 at the close on October 21, 2026: −74.67% in total, −12.83% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−54.54%
2025+84.13%
2024+13.51%
2023−42.90%
2022−52.90%
2021+19.41%
2020−19.93%
2019−37.20%
2018+71.91%
2017−4.70%
2016 (partial year)+31.49%

As of October 21, 2026.

VNDA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$216.11M−$220.47M−102.0%
2024$198.77M−$18.90M−9.5%
2023$192.64M$2.51M1.3%
2022$254.38M$6.28M2.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$216.11M$203.06M−$151.17M−$220.47M−102.0%
2024$198.77M$187.46M−$40.66M−$18.90M−9.5%
2023$192.64M$177.84M−$13.95M$2.51M1.3%
2022$254.38M$230.10M$6.33M$6.28M2.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VNDA Valuation vs Biotechnology Median

Median of 608 stocks
MetricVNDABiotechnology medianvs median
P/S ratio1.1213.300.1x the median
Profit margin−127.41%−38.31%89.1 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Vanda Pharmaceuticals Inc. (VNDA) at $242.46M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 533.

VNDA last closed at $4.01 on October 21, 2026. That is −$0.16 (−3.84%) against the previous close. Over the past 52 weeks the price has ranged from $3.97 to $9.94. The latest close sits 1.13% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $216.11M. Against the prior fiscal year total of $198.77M, that is a change of +8.72%. The same year closed with a net loss of $220.47M. The reported profit margin is −127.41%. That is 89.1 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −4.63.

Across the 4 fiscal years on file, revenue moves from $254.38M in 2022 to $216.11M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 20.05. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.23. Measured against sales, the shares trade at 1.12 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −24.20%. Across 10 years the annualized return works out at −12.83%. Beta against the wider market is reported at 0.69. Annualized volatility over the trailing 10 years is 55.29%.

Growth & Income

No dividend is on file for VNDA.

2026 is still running; the total return is −54.54% year to date. Across the complete calendar years on file, 2025 returned +84.13% and 2022 returned −52.90%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Vanda Pharmaceuticals Inc. (VNDA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Vanda Pharmaceuticals Inc. VNDA $242.46M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Vanda Pharmaceuticals Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Visit website →